该产品被引用文献
1, Klausberger, M; et al. A comprehensive antigen production and characterization study for easy-to-implement, highly specific and quantitative SARS-CoV-2 antibody assays. medRxiv
2, Sakharkar, M; et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. Science immunology, Pubmed: 33622975
3, Klausberger, M; et al. A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests. EBioMedicine, Pubmed: 33906067
4, Ravindran, R; et al. Immune response dynamics in COVID-19 patients to SARS-CoV-2 and other human coronaviruses. PloS one, Pubmed: 34242356
5, Jennewein, MF; et al. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell reports, Pubmed: 34237283
6, Natarajan, H; et al. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. mBio, Pubmed: 33879585
7, Wratil, PR; et al. Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses. Cell reports, Pubmed: 34932974
8, Lin, CY; et al. Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response. Cell host & microbe, Pubmed: 34965382
9, Narowski, TM; et al. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people. Cell reports, Pubmed: 35090596
10, Lederer, K; et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell, Pubmed: 35202565
11, Pattinson, D; et al. A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs. Viruses, Pubmed: 35336970
12, Minervina, AA; et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8 T cells. medRxiv : the preprint server for health sciences, Pubmed: 34341799
13, Lanz, TV; et al. Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2. Research square, Pubmed: 35441169
14, Minervina, AA; et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nature immunology, Pubmed: 35383307
15, Sun, X; et al. Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nature microbiology, Pubmed: 35773398
16, Khan, I; et al. Dynamics of Temporal Immune Responses in Nonhuman Primates and Humans Immunized with COVID-19 Vaccines. Research Square
17, Anderson, EM; et al. SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared with SARS-CoV-2 mRNA vaccinations. Cell reports, Pubmed: 36261003
18, Yu, J; et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood, Pubmed: 32877502
19, De Assis, RR; et al. Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Blood using a Coronavirus Antigen Microarray. BioRxiv
20, Khan, S; et al. Analysis of Serologic Cross-Reactivity Between Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray. BioRxiv
21, Liu, D; et al. Ultra-sensitive nanozyme-based chemiluminescence paper test for rapid diagnosis of SARS-CoV-2 infection. bioRxiv
22, Steiner, D; et al. Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients. bioRxiv
23, Zhou, D; et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. bioRxiv
24, López-Muñoz, AD; Santos, JJS; Yewdell, JW. Cell Surface Nucleocapsid Protein Expression: A Betacoronavirus Immunomodulatory Strategy. bioRxiv : the preprint server for biology, Pubmed: 36993159
25, Guzman Martinez, O. Evaluación de factores que influyen en la severidad de la infección por SARS-CoV-2. Thesis